These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 11138685

  • 1. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
    Colnot DR, Wilhelm AJ, Cloos J, Roos JC, de Bree R, Quak JJ, Snow GB, van Dongen GA.
    J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
    [Abstract] [Full Text] [Related]

  • 3. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [Abstract] [Full Text] [Related]

  • 4. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
    Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Börjesson PK, Huijgens PC, Snow GB, van Dongen GA.
    Clin Cancer Res; 2002 Nov 01; 8(11):3401-6. PubMed ID: 12429627
    [Abstract] [Full Text] [Related]

  • 5. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 01; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 6. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 7. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
    Gerretsen M, Visser GW, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.
    Cancer Res; 1993 Aug 01; 53(15):3524-9. PubMed ID: 8339258
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
    Colnot DR, Quak JJ, Roos JC, de Bree R, Wilhelm AJ, Snow GB, van Dongen GA.
    Head Neck; 2001 Jul 01; 23(7):559-65. PubMed ID: 11400244
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 01; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 11. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
    van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA.
    Cancer; 1997 Dec 15; 80(12 Suppl):2360-70. PubMed ID: 9406684
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC.
    J Nucl Med; 1992 Jun 15; 33(6):1099-109. PubMed ID: 1597723
    [Abstract] [Full Text] [Related]

  • 13. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB, Fisher DR, Wessels BW.
    J Nucl Med; 1998 Oct 15; 39(10):1746-51. PubMed ID: 9776281
    [Abstract] [Full Text] [Related]

  • 14. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P.
    Obstet Gynecol; 1993 Oct 15; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA.
    Cancer Res; 1995 Mar 01; 55(5):1060-9. PubMed ID: 7866989
    [Abstract] [Full Text] [Related]

  • 16. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
    Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2133-40. PubMed ID: 16609026
    [Abstract] [Full Text] [Related]

  • 17. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug 01; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 18. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J.
    J Nucl Med; 2006 Feb 01; 47(2):247-55. PubMed ID: 16455630
    [Abstract] [Full Text] [Related]

  • 19. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
    Cheng J, Ekberg T, Engström M, Nestor M, Jensen HJ, Tolmachev V, Anniko M.
    Laryngoscope; 2007 Jun 01; 117(6):1013-8. PubMed ID: 17440426
    [Abstract] [Full Text] [Related]

  • 20. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, Perera A, Peña Y, Hernández A, Sanchez Y, Romero S, Leyva R, Prats A, Fernandez R.
    Nucl Med Commun; 2008 Jan 01; 29(1):66-75. PubMed ID: 18049099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.